GlassScriptPhysician profile
Elizabeth Beaver
NPI 1174915839
$3,885.54
in general payments reported to CMS, 2019-2025
31 companies · $664 in 2025
The $664 reported for 2025 was more than what 91% of Women'S Health (Nurse Practitioner) providers received nationally (typical 2025 total: $123).
See the full distribution for Women's Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $575 · 2022: $881 · 2023: $982 · 2024: $783 · 2025: $664.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,429.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,429.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $755.88 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $349.47 | 2021-2025 | |
| Mayne Pharma Commercial LLC | $348.24 | 2021-2025 | |
| Exeltis, USA INC. | $242.39 | 2021-2025 | Slynd |
| Sumitomo Pharma America, INC. | $232.31 | 2023-2025 | Myfembree |
| Organon LLC | $186.73 | 2021-2025 | Nexplanon, Nuvaring, Jada System |
| Myovant Sciences INC. | $171.65 | 2021-2022 | |
| Coopersurgical, INC. | $169.92 | 2022-2024 | Paragard T 380a, Paragard T 380a, Summit Doppler |
| Astellas Pharma US INC | $168.59 | 2023-2025 | Veozah |
| Evofem Biosciences, INC. | $145.84 | 2021-2023 | Phexxi |
| Biogen, INC. | $133.68 | 2024-2025 | Zurzuvae |
| Gilead Sciences, INC. | $124.54 | 2023 | Biktarvy |
| Daiichi Sankyo INC. | $116.88 | 2021 | |
| Shield Therapeutics INC | $93.12 | 2022-2025 | |
| Caldera Medical, INC | $92.97 | 2021 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $80.84 | 2024-2025 | Interstim, Venaseal |
| Scynexis, INC. | $60.89 | 2022 | |
| Myriad Women'S Health, INC. | $59.43 | 2023 | Myrisk |
| Baxter Healthcare | $58.03 | 2023-2025 | Tisseel |
| Millicent US INC | $51.67 | 2024-2025 | Intrarosa, Femlyv, Femring |
| Ethicon US, LLC | $32.85 | 2023 | Harmonic, Stratafix |
| Mylan Pharmaceuticals INC. | $32.53 | 2021-2022 | |
| Therapeuticsmd, INC. | $26.60 | 2021-2022 | |
| Hologic Sales and Service, LLC | $26.24 | 2024 | Myosure Tissue Removal Device, Novasure, Omni Hysteroscope |
| Aspira Women'S Health INC | $21.70 | 2024 | Ova1 |
| Merck Sharp & Dohme LLC | $20.48 | 2024 | Gardasil 9, Gardasil |
| Boston Scientific Corporation | $19.80 | 2022 | |
| Avion Pharmaceuticals | $18.31 | 2022 | |
| Lupin INC. | $15.19 | 2021 | |
| Smith+Nephew, INC. | $14.75 | 2024 | Pico 7, Pico 14 |
| Exact Sciences Corporation | $14.02 | 2025 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth Beaver listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.